Once More Unto The Breach: 2014 NME Candidates Crowd In Familiar Fields
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With new drug candidates concentrated in already crowded markets like diabetes, antithrombotics and oncology, in 2014 sponsors must be prepared to demonstrate value not just to regulators but to payers as well. Merck, Lilly and AstraZeneca account for one-third of pending novel agents as the companies seek to recover from the patent cliff.